RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma Ltd. received a Nasdaq Staff Determination notification on October 16, 2025, indicating non-compliance with the minimum stockholders’ equity requirements for continued listing. The company believes that its recent transaction with Cumberland Pharmaceuticals Inc. has increased its stockholders’ equity above the $2.5 million minimum requirement. RedHill intends to appeal the determination to a Nasdaq Hearings Panel, which has the authority to grant an extension of up to 180 days to regain compliance. The company remains listed on the Nasdaq Capital Market pending the hearing outcome. However, there is no assurance that the Panel will grant an extension or that the outcome will be favorable.